Center Care (Meritain) policies, page 2

Search Center Care (Meritain)'s public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

109 policies name 96413, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Center Care (Meritain) policies
PolicyDetailsCodesSource
1089-Linvoseltamab-gcpt (Lynozyfic)1089 · Commercial13Original policy ↗
Cabazitaxel (Jevtana)0806 · Commercial13Original policy ↗
0815-Ipilimumab (Yervoy)0815 · Commercial14Original policy ↗
0958-Gemcitabine0958 · Commercial14Original policy ↗
0969-Isatuximab-irfc (Sarclisa)0969 · Commercial14Original policy ↗
1056-Lifileucel (Amtagvi)1056 · Commercial14Original policy ↗
0995-Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro)0995 · Commercial15Original policy ↗
1007-Ciltacabtagene Autoleucel (Carvykti)1007 · Commercial15Original policy ↗
1048-Mirikizumab-mrkz (Omvoh)1048 · Commercial15Original policy ↗
ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP)0780 · Commercial15Original policy ↗
0834-Paclitaxel, Albumin-Bound0834 · Commercial16Original policy ↗
1022-Teplizumab-mzwv (Tzield)1022 · Commercial16Original policy ↗
1006-Sutimlimab-jome (Enjaymo)1006 · Commercial17Original policy ↗
1018-Teclistamab-cqyv (Tecvayli)1018 · Commercial17Original policy ↗
0748-Panitumumab (Vectibix)0748 · Commercial18Original policy ↗
Betibeglogene Autotemcel (Zynteglo)1016 · Commercial18Original policy ↗
0940-Mogamulizumab-kpkc (Poteligeo)0940 · Commercial19Original policy ↗
0971-Sacituzumab govitecan-hziy (Trodelvy)0971 · Commercial19Original policy ↗
0874-Radium Ra 223 Dichloride (Xofigo)0874 · Commercial20Original policy ↗
0876-Temozolomide (Temodar) Injection0876 · Commercial21Original policy ↗
0902-Irinotecan Liposome Injection (Onivyde)0902 · Commercial21Original policy ↗
1026-Lecanemab-irmb (Leqembi)1026 · Commercial21Original policy ↗
Enfortumab Vedotin-ejfv (Padcev)0967 · Commercial21Original policy ↗
Ixabepilone (Ixempra)0869 · Commercial22Original policy ↗
0675-Bortezomib Products0675 · Commercial23Original policy ↗
Retifanlimab-dlwr (Zynyz)1030 · Commercial23Original policy ↗
0883-Ramucirumab (Cyramza)0883 · Commercial24Original policy ↗
0884-Siltuximab (Sylvant)0884 · Commercial28Original policy ↗
1013-Spesolimab-sbzo (Spevigo)1013 · Commercial28Original policy ↗
1075-Zanidatamab-hrii (Ziihera)1075 · Commercial30Original policy ↗
0993-Dostarlimab-gxly (Jemperli)0993 · Commercial31Original policy ↗
0867-Clofarabine0867 · Commercial32Original policy ↗
0875-Bendamustine Products0875 · Commercial34Original policy ↗
0955-Polatuzumab vedotin-piiq (Polivy)0955 · Commercial34Original policy ↗
Pemetrexed Products0687 · Commercial35Original policy ↗
0929-Lutetium Lu Dotatate (Lutathera) and Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto)0929 · Commercial37Original policy ↗
0845-Carfilzomib (Kyprolis)0845 · Commercial38Original policy ↗
0997-Anifrolumab-fnia (Saphnelo)0997 · Commercial38Original policy ↗
0024-Aldesleukin (Proleukin)0024 · Commercial39Original policy ↗
0807-Eculizumab0807 · Commercial39Original policy ↗
0904-Daratumumab (Darzalex) and Daratumumab and Hyaluronidase-fihj (Darzalex Faspro)0904 · Commercial39Original policy ↗
0905-Secukinumab (Cosentyx)0905 · Commercial39Original policy ↗
0917-Durvalumab (Imfinzi)0917 · Commercial41Original policy ↗
Atezolizumab (Tecentriq) and Atezolizumab and Hyaluronidase-tqjs (Tecentriq Hybreza)0909 · Commercial46Original policy ↗
1102-Marnetegragene Autotemcel (Kresladi)1102 · Commercial48Original policy ↗
0877-Obinutuzumab (Gazyva)0877 · Commercial52Original policy ↗
0885-Vedolizumab (Entyvio)0885 · Commercial52Original policy ↗
0812-Hypoxic Ischemic Encephalopathy0812 · Commercial53Original policy ↗
0978-Lurbinectedin (Zepzelca)0978 · Commercial53Original policy ↗
0892-Nivolumab Products (Opdivo, Opdivo Qvantig, and Opdualag)0892 · Commercial58Original policy ↗

Back to Center Care (Meritain)

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.